Cytomel (Liothyronine) and Tadalafil Interaction: What Patients and Clinicians Need to Know

What Is the Interaction Between Liothyronine and Tadalafil?

The interaction between liothyronine and tadalafil is pharmacodynamic rather than pharmacokinetic. Liothyronine is not metabolized by cytochrome P450 enzymes; it undergoes peripheral deiodination and glucuronide conjugation. Tadalafil is primarily a CYP3A4 substrate. Because neither drug competes for the same metabolic pathway, plasma concentrations of each are unlikely to change when they are combined.

The real concern is cardiovascular hemodynamics. Excess thyroid hormone increases heart rate, stroke volume, and myocardial oxygen demand. Tadalafil reduces systemic vascular resistance by preventing the breakdown of cyclic GMP in vascular smooth muscle. Combining these two effects in a patient whose T3 is even mildly supraphysiologic could tip the balance toward tachycardia, palpitations, or symptomatic hypotension.

How Liothyronine Affects the Cardiovascular System

Thyroid hormones act on cardiac myocytes through genomic and non-genomic pathways. Genomic effects increase expression of the sarcoplasmic reticulum Ca²⁺-ATPase (SERCA2a) and the alpha-myosin heavy chain, both of which speed contraction and relaxation. Non-genomic effects open ion channels within minutes, raising resting heart rate even before gene transcription changes.

A 2019 review published in the Journal of Clinical Endocrinology and Metabolism confirmed that even mild subclinical hyperthyroidism (TSH <0.1 mIU/L) is associated with a two-fold increase in atrial fibrillation risk compared with euthyroid controls, with a hazard ratio of 2.54 (95% CI 1.06 to 6.09) [1]. Keeping T3 replacement within the therapeutic window is therefore not optional for patients who also take vasodilating agents.

How Tadalafil Affects Systemic Blood Pressure

Tadalafil inhibits PDE5, the enzyme that degrades cyclic GMP in smooth muscle cells. The resulting vasodilation lowers mean arterial pressure by roughly 8 to 10 mmHg systolic and 4 to 6 mmHg diastolic under standard 20 mg dosing, according to the FDA-approved prescribing information for Adcirca (tadalafil) [2]. At the 5 mg daily dose used for erectile dysfunction maintenance therapy, the hemodynamic shift is smaller but still measurable.

When cardiac output is simultaneously elevated by excess T3, the heart is asked to do more work against a lower resistance. For a healthy euthyroid patient this combination is generally well tolerated. For a patient with hypothyroid cardiomyopathy, arrhythmia history, or coronary artery disease, the margin narrows.

Mechanism Deep-Dive: Why There Is No CYP Interaction

Liothyronine Metabolism

Liothyronine (3,5,3'-triiodothyronine) is absorbed in the small intestine, reaches peak serum concentration in 2 to 4 hours, and has a half-life of approximately 1 day. Metabolism occurs primarily through deiodination in the liver, kidney, and peripheral tissues, producing T2 and ultimately inorganic iodide. Glucuronidation and sulfation account for biliary excretion. No CYP1A2, CYP2C9, CYP2D6, or CYP3A4 involvement has been established in primary literature or in the FDA label for Cytomel [3].

Tadalafil Metabolism

Tadalafil is predominantly metabolized by CYP3A4 to an inactive catechol methylated metabolite. Co-administration with strong CYP3A4 inhibitors such as ketoconazole raises tadalafil AUC by up to 312%, as noted in the Cialis prescribing information [4]. Liothyronine does not inhibit or induce CYP3A4, so this interaction pathway is not relevant when the two drugs are combined.

P-Glycoprotein Considerations

P-glycoprotein (P-gp) is an efflux transporter relevant to some thyroid hormone analogs. Published in vitro data suggest liothyronine has minimal P-gp affinity compared with levothyroxine, and tadalafil is not a P-gp substrate of clinical significance. A 2016 pharmacokinetic analysis in Drug Metabolism and Disposition found no transporter-mediated changes in thyroid hormone handling when common co-medications were added [5]. This further supports characterizing the liothyronine-tadalafil interaction as purely pharmacodynamic.

Clinical Severity: How Dangerous Is This Combination?

This interaction is rated moderate in standard DDI databases, not contraindicated. That rating reflects two facts: the interaction requires an out-of-range T3 level to become clinically significant, and it is largely reversible through dose adjustment.

Patients at Lower Risk

A euthyroid patient taking liothyronine 25 mcg daily (or a stable combination T4/T3 dose) whose TSH sits comfortably between 0.5 and 2.5 mIU/L is unlikely to experience symptomatic hemodynamic effects from adding tadalafil 5 mg or 10 mg. Heart rate and blood pressure should still be checked at baseline and at the first follow-up visit.

Patients at Higher Risk

Three groups warrant extra caution:

• Patients with TSH persistently <0.1 mIU/L (biochemical hyperthyroidism from over-replacement)
• Patients with a history of paroxysmal atrial fibrillation, coronary artery disease, or heart failure with reduced ejection fraction
• Patients simultaneously taking alpha-blockers such as tamsulosin, which also lower blood pressure and can combine additively with tadalafil

The ACC/AHA 2022 Guideline on Chest Pain Evaluation explicitly notes that PDE5 inhibitors are contraindicated with nitrates and require caution in any setting that independently raises cardiac demand [6].

The Nitrate Absolute Contraindication

If a patient takes any nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) alongside tadalafil, co-prescribing is absolutely contraindicated regardless of thyroid status. The FDA label for tadalafil states that nitrate co-administration "could result in a severe decrease in blood pressure" [4]. Adding liothyronine to a nitrate-plus-tadalafil regimen would compound the problem further. Screen all patients for nitrate use before prescribing either agent.

Pharmacodynamic Overlap: The Heart Rate Problem

Heart rate is the most sensitive clinical indicator of this interaction. Thyroid hormone directly upregulates the sinoatrial node, and tadalafil's vasodilation reflexively increases sympathetic tone, which also raises heart rate. The net effect may be additive tachycardia.

A controlled crossover study published in the European Journal of Clinical Pharmacology showed that vasodilating PDE5 inhibitors produce a mean increase of 4 to 6 beats per minute at rest in healthy volunteers [7]. Layered onto a T3-driven baseline elevation of 8 to 12 bpm seen in mild hyperthyroidism, total resting tachycardia could easily exceed 100 bpm in susceptible individuals.

Sustained resting heart rate above 100 bpm in the context of exogenous thyroid hormone should prompt same-week TSH and free T3 measurement, a review of tadalafil dose, and a 12-lead ECG if palpitations are reported.

Monitoring Parameters

The following monitoring framework applies to any patient co-prescribed liothyronine and tadalafil. It is organized by timepoint and integrates guidance from the American Thyroid Association 2014 Hypothyroidism Guidelines and the tadalafil FDA prescribing information [3, 4, 8].

Baseline (Before Starting Either Drug)

• Resting heart rate and blood pressure (seated, after 5 minutes)
• 12-lead ECG if the patient is over age 40 or has cardiac history
• TSH and free T3 (or free T4 if on T4 monotherapy transitioning to combination)
• Medication reconciliation for nitrates, alpha-blockers, antihypertensives, antiarrhythmics
• Renal function (tadalafil dose adjustment required at GFR <30 mL/min)

Weeks 4 to 8 After Starting or Adjusting Liothyronine

• Repeat TSH and free T3
• Repeat blood pressure and heart rate
• Ask directly about palpitations, dyspnea on exertion, lightheadedness, and headache

Ongoing (Every 6 Months if Stable)

• TSH target confirmation (0.5 to 2.5 mIU/L for most adults on replacement)
• Blood pressure check
• Brief cardiovascular symptom review

A 2021 study in Thyroid found that 43% of patients on liothyronine-containing regimens had at least one out-of-range free T3 measurement during the first year of therapy, underscoring the need for regular lab review rather than a set-and-forget approach [9].

Dose Considerations

Liothyronine Dosing in the Context of Tadalafil Use

The American Thyroid Association recommends starting liothyronine at low doses (5 mcg once or twice daily) and titrating by 5 mcg increments every 4 weeks to reach euthyroid status [8]. For patients already on tadalafil, staying at the lower end of the titration range until TSH is confirmed in range reduces cardiovascular risk during the adjustment period.

Splitting the liothyronine dose (e.g., 10 mcg in the morning and 10 mcg at midday rather than 25 mcg once daily) produces a flatter free T3 curve and avoids the 2 to 4 hour peak that drives acute heart rate elevation. This approach has pharmacokinetic support in a 2019 pharmacokinetic modeling study in Thyroid [10].

Tadalafil Dosing Adjustments

No adjustment to tadalafil dose is pharmacokinetically required based on liothyronine co-administration. The choice between 5 mg daily dosing versus 10 to 20 mg on-demand dosing should incorporate the patient's cardiovascular baseline. For patients with marginally elevated baseline heart rate or blood pressure due to suboptimal thyroid status, the lower 5 mg daily option produces a smaller hemodynamic perturbation and allows time for thyroid optimization.

Drug Interactions Beyond Tadalafil: Context for Liothyronine Patients

Liothyronine has several other clinically relevant interactions that prescribers managing patients on multiple agents should recognize.

Anticoagulants

Thyroid hormones potentiate the effects of warfarin by accelerating factor degradation. The FDA label for Cytomel specifically warns that patients stabilized on warfarin may need dose reduction of up to 30% when thyroid replacement is started or increased [3]. Tadalafil itself does not significantly interact with warfarin.

Sympathomimetics

Combining liothyronine with epinephrine, pseudoephedrine, or other sympathomimetics amplifies the cardiovascular effects of both agents. The Cytomel prescribing information notes this risk explicitly [3]. Patients using tadalafil for erectile dysfunction who also self-administer sympathomimetic-containing supplements face a three-way cardiovascular stress that should trigger a clinical conversation.

Calcium, Iron, and Absorption Inhibitors

Calcium carbonate, ferrous sulfate, proton pump inhibitors, and cholestyramine all reduce liothyronine absorption when taken within 4 hours of the dose. A 2017 systematic review in Thyroid confirmed that calcium supplements reduce levothyroxine absorption by up to 40%; liothyronine is likely subject to similar interference [11]. Tadalafil is not affected by these agents.

Patient Counseling Points

Clinicians should cover these specific points when a patient is co-prescribed both drugs:

Recognize warning symptoms. Palpitations, chest tightness, sudden dizziness on standing, or unexplained shortness of breath while on both drugs warrant same-day contact with the prescribing provider. These may signal either supraphysiologic T3 levels or additive vasodilation.

Take liothyronine on an empty stomach. The Cytomel label recommends administration 30 to 60 minutes before food to maximize absorption [3]. Consistency in dosing time reduces free T3 variability and makes TSH results more interpretable.

Do not combine tadalafil with nitrates. This is non-negotiable. Patients who develop chest pain and carry sublingual nitroglycerin must not use it within 48 hours of tadalafil, and should have an alternative nitrate-free angina management plan documented in their chart.

Avoid dose stacking. Some patients on TRT (testosterone replacement therapy) receive tadalafil for erections and liothyronine for metabolic optimization. Adding other supplements with cardiovascular activity (yohimbine, high-dose caffeine, DMHA) raises baseline sympathetic tone further. The prescriber should ask specifically about these at every refill.

Keep a consistent daily schedule. Taking liothyronine at the same time each day, ideally separated from tadalafil by at least 2 hours during the peak absorption window, allows each drug's hemodynamic effects to be assessed independently rather than simultaneously.

Special Populations

Men on TRT Plus Liothyronine Plus Tadalafil

This combination is increasingly common in men's health telehealth. Testosterone itself raises red blood cell mass and may mildly increase blood pressure. Adding liothyronine accelerates cardiac output. Adding tadalafil then drops resistance. A 2020 study in the Journal of Sexual Medicine found that 22% of men presenting to sexual health clinics were taking at least two cardiovascular-active agents concurrently with PDE5 inhibitors [12]. Every patient in this category needs a documented cardiovascular risk assessment before the combination is continued.

Women on HRT Plus Liothyronine

Estrogen-containing hormone replacement therapy increases thyroid-binding globulin, which lowers free T3 and T4. Women transitioning from levothyroxine monotherapy to combination T4/T3 who are also on estrogen may need higher total thyroid hormone doses to maintain the same free fraction. Tadalafil is approved for pulmonary arterial hypertension in women (as Adcirca 40 mg daily); for these patients, cardiovascular monitoring is already part of standard disease management per the FDA Adcirca label [2].

Older Adults (>65 Years)

Older adults have reduced cardiovascular reserve, higher baseline prevalence of atrial fibrillation, and slower liothyronine clearance. The ATA guideline recommends lower starting doses (5 mcg daily) and longer titration intervals (6 to 8 weeks rather than 4) in patients over 65 [8]. Tadalafil 5 mg is preferred over 10 to 20 mg on-demand dosing in this age group given the larger hemodynamic footprint of higher doses.

What the Evidence Does Not Yet Show

No prospective randomized controlled trial has specifically studied the liothyronine-tadalafil combination in terms of blood pressure outcomes, arrhythmia incidence, or quality-of-life endpoints. The interaction classification comes from pharmacodynamic inference, case reports, and extrapolation from thyroid hormone physiology studies rather than a dedicated drug-drug interaction trial. Clinicians should document this uncertainty in shared decision-making conversations with patients.

Observational data from electronic health records could fill this gap. HealthRX's clinical team is currently analyzing outcomes in patients co-prescribed thyroid hormones and PDE5 inhibitors; preliminary internal review suggests resting heart rate above 90 bpm at a follow-up visit is the most common flag that prompts a liothyronine dose adjustment in this population.